Experimental study of anti-inflammatory properties of exposure “Venosten”





anti-inflammatory activity, “Venosten” thick extract, carrageenan edema, zymosan edema


Topicality. The presence of inflammatory process in diseases of veins caused the study of anti-inflammatory activity of the dense extract “Venosten”, which was investigated on models of inflammation with various mechanisms of development: carragenin and zimozanovyh edema.

The aim of this work was to study the anti-inflammatory properties of the new dense “Venosten” extract in the dose range and establish an effective dose for this type of pharmacological activity.

Materials and methods. At the first stage of the study, the study of anti-inflammatory properties on the model of carrageenan edema in rats. It is known that in the pathogenesis of carrageenitis inflammation in 1.5-5.5 hours after the introduction of flogogenic GHG plays a leading role, this allows us to conclude about the effect of the investigated extract on the cyclooxygenase system. In order to establish the ability of the thick extract of “Venosten” to suppress the activity of the key enzymes of the transformation of arachidonic acid in the next stage, we used a model of zymosan edema, whose mechanism of development is the formation of LT (0.5 hours). The anti-inflammatory activity of the thick extract “Venosten” was studied in doses 25 mg/kg, 50 mg/kg and 100 mg/kg.

Results and discussion. The essential extract of “Venosten” in a dose of 100 mg/kg reduced the new caraphaea by a new swelling by 3 hours in 1.8 times (anti-eczual activity 42.2 %). Pre-administration of the “Venosten” Extract of 100 mg/kg significantly impairs the development of zymosan edema. Thus, 0.5 hours after the administration of zymosan to animals, in the rat treated with the “Venosten” extract, the edema was significantly lower than 1.5 times in the control group of pathology. The anti-exudative activity was 32.6 %.

Conclusions. Extract “Venosten” in a dose of 100 mg/kg showed a pronounced anti-exudative activity and the ability to suppress the synthesis of prostaglandins and moderately affect the synthesis of leukotrienes.

Author Biographies

A. L. Zagayko, National University of Pharmacy

d. biol. s., professor, Vice-Rector for scientific and pedagogical work

O. S. Kukhtenko, National University of Pharmacy

Candidate (PhD) of Pharmaceutical Sciences, Associate Professor, Vice-Rector for scientific and pedagogical (educative) work

L. V. Galuzinska, National University of Pharmacy

Candidate of Pharmacy (Ph. D), associate professor of Department of the biological chemistry department

P. I. Bushin, National University of Pharmacy

2-nd year student of the 4-th group of the specialty “Pharmacy”


1. Mishalov, V. G., Osadii, A. I., Seliuk, V. M. (2002). Hirurhiia Ukrainy, 2, 92-94.

2. Kharkevich, D. A. (2004). Eksperimentalnaia i klinicheskaia farmakologiia, 1, 69–77.

3. Nemchenko, A. S., Kukhtenko, O. S., Gladukh, I. V. (2017). Marketing research of the pharmaceutical market of drugs for treating varicose veins and inflammatory diseases of joints. Socìal’na Farmacìâ v Ohoronì Zdorov’â, 3 (3), 66–73. doi: 10.24959/sphhcj.17.87

4. Kukhtenko, O. S., Hladukh, E. V. (2016). Naukovo-tekhnichnyi prohres i optymizatsiia tekhnolohichnykh protsesiv stvorennia likarskykh preparativ. Ternopil: TDMU, 129-130.

5. Kukhtenko, A. S., Gladuh, E. V. (2015). Aktualnye voprosy obrazovaniia, nauki i proizvodstva v farmatcii. Toshkent, 109-110.

6. Kaminska, O. L., Kuhtenko, O. S. (2014). Tekhnolohichni ta biofarmatsevtychni aspekty stvorennia likarskykh preparativ riznoi napravlenosti dii. Kharkiv, 83.

7. Stefanov, O. V. (2001). Doklіnichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena, 528.

8. Gado, K., Gigler, G. (1991). Zymozaninflammation. A newmethodsuitablefor: evaluatingnew anti-inflammatorydrugs. AgentsandActions, 32 (1-2), 119 – 121.





No Section